Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Diseases
Visually Identified Tau 18f-Mk6240 Pet Patterns In Symptomatic Alzheimer's Disease, Natasha Krishnadas, Kun Huang, Stephanie A. Schultz, Vincent Doré, Pierrick Bourgeat, Anita M. Y. Goh, Fiona Lamb, Svetlana Bozinovski, Samantha C. Burnham, Joanne S. Robertson, Simon M. Laws, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe
Visually Identified Tau 18f-Mk6240 Pet Patterns In Symptomatic Alzheimer's Disease, Natasha Krishnadas, Kun Huang, Stephanie A. Schultz, Vincent Doré, Pierrick Bourgeat, Anita M. Y. Goh, Fiona Lamb, Svetlana Bozinovski, Samantha C. Burnham, Joanne S. Robertson, Simon M. Laws, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe
Research outputs 2022 to 2026
Background: In Alzheimer's disease, heterogeneity has been observed in the postmortem distribution of tau neurofibrillary tangles. Visualizing the topography of tau in vivo may facilitate clinical trials and clinical practice. Objective: This study aimed to investigate whether tau distribution patterns that are limited to mesial temporal lobe (MTL)/limbic regions, and those that spare MTL regions, can be visually identified using 18F-MK6240, and whether these patterns are associated with different demographic and cognitive profiles. Methods : Tau 18F-MK6240 PET images of 151 amyloid-β positive participants with mild cognitive impairment (MCI) and dementia were visually rated as: tau negative, limbic predominant (LP), …
Plasma P217+Tau Versus Nav4694 Amyloid And Mk6240 Tau Pet Across The Alzheimer's Continuum, Vincent Doré, James D. Doecke, Ziad S. Saad, Gallen Triana-Baltzer, Randy Slemmon, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Samantha Burnham, Christopher Fowler, Stephanie R. Rainey-Smith, Ashley I. Bush, Larry Ward, Jo Robertson, Ralph N. Martins, Colin L. Masters, Victor L. Villemagne, Jurgen Fripp, Hartmuth C. Kolb, Christopher C. Rowe
Plasma P217+Tau Versus Nav4694 Amyloid And Mk6240 Tau Pet Across The Alzheimer's Continuum, Vincent Doré, James D. Doecke, Ziad S. Saad, Gallen Triana-Baltzer, Randy Slemmon, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Samantha Burnham, Christopher Fowler, Stephanie R. Rainey-Smith, Ashley I. Bush, Larry Ward, Jo Robertson, Ralph N. Martins, Colin L. Masters, Victor L. Villemagne, Jurgen Fripp, Hartmuth C. Kolb, Christopher C. Rowe
Research outputs 2022 to 2026
Introduction: We evaluated a new Simoa plasma assay for phosphorylated tau (P-tau) at aa217 enhanced by additional p-tau sites (p217+tau). Methods: Plasma p217+tau levels were compared to 18F-NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F-MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results: Compared to Aβ− CU, the plasma levels of p217+tau increased 2-fold in Aβ+ CU and 3.5-fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P =.67 (CI, P =.64; CU, P =.45) and tau SUVRMT P …
Plasma P-Tau181/Aβ1-42 Ratio Predicts Aβ-Pet Status And Correlates With Csf-P-Tau181/Aβ1-42 And Future Cognitive Decline, Christopher J. Fowler, Erik Stoops, Stephanie R. Rainey-Smith, Eugeen Vanmechelen, Jeroen Vanbrabant, Nele Dewit, Kimberley Mauroo, Paul Maruff, Christopher C. Rowe, Jurgen Fripp, Qiao-Xin Li, Pierrick Bourgeat, Steven J. Collins, Ralph N. Martins, Colin L. Masters, James D. Doecke
Plasma P-Tau181/Aβ1-42 Ratio Predicts Aβ-Pet Status And Correlates With Csf-P-Tau181/Aβ1-42 And Future Cognitive Decline, Christopher J. Fowler, Erik Stoops, Stephanie R. Rainey-Smith, Eugeen Vanmechelen, Jeroen Vanbrabant, Nele Dewit, Kimberley Mauroo, Paul Maruff, Christopher C. Rowe, Jurgen Fripp, Qiao-Xin Li, Pierrick Bourgeat, Steven J. Collins, Ralph N. Martins, Colin L. Masters, James D. Doecke
Research outputs 2022 to 2026
Background: In Alzheimer's disease (AD), plasma amyloid beta (Aβ)1-42 and phosphorylated tau (p-tau) predict high amyloid status from Aβ positron emission tomography (PET); however, the extent to which combination of these plasma assays can predict remains unknown. Methods: Prototype Simoa assays were used to measure plasma samples from participants who were either cognitively normal (CN) or had mild cognitive impairment (MCI)/AD in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Results: The p-tau181/Aβ1-42 ratio showed the best prediction of Aβ-PET across all participants (area under the curve [AUC] = 0.905, 95% confidence interval [CI]: 0.86–0.95) and in CN (AUC = …